MRE-269

SKU: orb1303362

Description

MRE-269 (ACT-333679) is the long-acting, orally active metabolite of Selexipag and a potent prostacyclin receptor (IP receptor) agonist. It is utilized in pulmonary arterial hypertension (PAH) research, with studies demonstrating its efficacy in both in vitro assays and in vivo animal models of pulmonary hypertension.

Research Area

Immunology & Inflammation, Pharmacology & Drug Discovery

Key Properties

• CAS Number: 475085-57-5
• MW: 419.52
• Purity: 99.57% (May vary between batches)
• Formula: C₂₅H₂₉N₃O₃
• SMILES: N(CCCCOCC(O)=O)(C(C)C)C=1N=C(C(=NC1)C2=CC=CC=C2)C3=CC=CC=C3
• Target: Prostaglandin Receptor
• Solubility: DMSO:55 mg/mL (131.1 mM);10% DMSO+90% Corn Oil:2.5 mg/mL (5.96 mM)

Bioactivity

• Target IC50:
  IP receptor (human):20 nM(Ki)

Storage & Handling

• Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

ACT 333679, ACT-333679, ACT333679, MRE 269, MRE269, MRE-269, inhibit, Inhibitor, ProstaglandinReceptor, prostaglandin I2 receptor, Prostaglandin Receptor

Compound Identifiers

PubChem CID

9931891